Catalyst Pharmaceuticals (CPRX) Operating Income Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.52% |
| Dec 31, 2025 | 48.31% |
| Sep 30, 2025 | 41.45% |
| Jun 30, 2025 | 45.17% |
| Mar 31, 2025 | 42.72% |
| Dec 31, 2024 | 50.99% |
| Sep 30, 2024 | 29.75% |
| Jun 30, 2024 | 37.69% |
| Mar 31, 2024 | 96.72% |
| Dec 31, 2023 | 36.90% |
| Sep 30, 2023 | -35.36% |
| Jun 30, 2023 | 56.44% |
| Mar 31, 2023 | 51.58% |
| Dec 31, 2022 | 49.98% |
| Sep 30, 2022 | 50.92% |
| Jun 30, 2022 | 54.60% |
| Mar 31, 2022 | 41.69% |
| Dec 31, 2021 | 37.72% |
| Sep 30, 2021 | 41.02% |
| Jun 30, 2021 | 39.54% |
| Mar 31, 2021 | 28.99% |
| Dec 31, 2020 | 27.67% |
| Sep 30, 2020 | 34.08% |
| Jun 30, 2020 | 32.60% |
| Mar 31, 2020 | 35.05% |
| Dec 31, 2019 | 32.02% |
| Sep 30, 2019 | 39.95% |
| Jun 30, 2019 | 41.46% |
| Mar 31, 2019 | 22.39% |
| Dec 31, 2018 | -40.54% |
| Sep 30, 2018 | -20.31% |
| Jun 30, 2018 | -19.01% |
| Mar 31, 2018 | -28.32% |
| Dec 31, 2017 | -29.64% |
| Sep 30, 2017 | -27.39% |
| Jun 30, 2017 | -31.40% |
| Mar 31, 2017 | -27.95% |
| Dec 31, 2016 | -16.22% |
| Sep 30, 2016 | -28.18% |
| Jun 30, 2016 | -28.07% |
| Mar 31, 2016 | -32.64% |
| Dec 31, 2015 | -53.26% |
| Sep 30, 2015 | -40.75% |